These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 21343701)
1. Epigenetic reprogramming as a key contributor to melanocyte malignant transformation. Molognoni F; Cruz AT; Meliso FM; Morais AS; Souza CF; Xander P; Bischof JM; Costa FF; Soares MB; Liang G; Jones PA; Jasiulionis MG Epigenetics; 2011 Apr; 6(4):450-64. PubMed ID: 21343701 [TBL] [Abstract][Full Text] [Related]
2. Mining gene expression signature for the detection of pre-malignant melanocytes and early melanomas with risk for metastasis. de Souza CF; Xander P; Monteiro AC; Silva AG; da Silva DC; Mai S; Bernardo V; Lopes JD; Jasiulionis MG PLoS One; 2012; 7(9):e44800. PubMed ID: 22984562 [TBL] [Abstract][Full Text] [Related]
3. Gene co-expression and histone modification signatures are associated with melanoma progression, epithelial-to-mesenchymal transition, and metastasis. Azevedo H; Pessoa GC; de Luna Vitorino FN; Nsengimana J; Newton-Bishop J; Reis EM; da Cunha JPC; Jasiulionis MG Clin Epigenetics; 2020 Aug; 12(1):127. PubMed ID: 32831131 [TBL] [Abstract][Full Text] [Related]
4. Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation. Toricelli M; Melo FH; Peres GB; Silva DC; Jasiulionis MG Mol Cancer; 2013 Mar; 12():22. PubMed ID: 23522389 [TBL] [Abstract][Full Text] [Related]
5. Ras and Rac1, frequently mutated in melanomas, are activated by superoxide anion, modulate Dnmt1 level and are causally related to melanocyte malignant transformation. Molognoni F; de Melo FH; da Silva CT; Jasiulionis MG PLoS One; 2013; 8(12):e81937. PubMed ID: 24358134 [TBL] [Abstract][Full Text] [Related]
6. The Roles of miR-26, miR-29, and miR-203 in the Silencing of the Epigenetic Machinery during Melanocyte Transformation. Gasque Schoof CR; Izzotti A; Jasiulionis MG; Vasques Ldos R Biomed Res Int; 2015; 2015():634749. PubMed ID: 26618174 [TBL] [Abstract][Full Text] [Related]
10. Tissue inhibitor of metalloproteinase 1 expression associated with gene demethylation confers anoikis resistance in early phases of melanocyte malignant transformation. Ricca TI; Liang G; Suenaga AP; Han SW; Jones PA; Jasiulionis MG Transl Oncol; 2009 Dec; 2(4):329-40. PubMed ID: 19956395 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment. Seftor EA; Brown KM; Chin L; Kirschmann DA; Wheaton WW; Protopopov A; Feng B; Balagurunathan Y; Trent JM; Nickoloff BJ; Seftor RE; Hendrix MJ Cancer Res; 2005 Nov; 65(22):10164-9. PubMed ID: 16288000 [TBL] [Abstract][Full Text] [Related]
12. Genome-wide promoter methylation profiling in a cellular model of melanoma progression reveals markers of malignancy and metastasis that predict melanoma survival. Rius FE; Papaiz DD; Azevedo HFZ; Ayub ALP; Pessoa DO; Oliveira TF; Loureiro APM; Andrade F; Fujita A; Reis EM; Mason CE; Jasiulionis MG Clin Epigenetics; 2022 May; 14(1):68. PubMed ID: 35606887 [TBL] [Abstract][Full Text] [Related]
13. Agglomerates of aberrant DNA methylation are associated with toxicant-induced malignant transformation. Severson PL; Tokar EJ; Vrba L; Waalkes MP; Futscher BW Epigenetics; 2012 Nov; 7(11):1238-48. PubMed ID: 22976526 [TBL] [Abstract][Full Text] [Related]
14. Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells. Ke XS; Qu Y; Cheng Y; Li WC; Rotter V; Øyan AM; Kalland KH BMC Genomics; 2010 Nov; 11():669. PubMed ID: 21108828 [TBL] [Abstract][Full Text] [Related]
15. Endothelial nitric oxide synthase uncoupling as a key mediator of melanocyte malignant transformation associated with sustained stress conditions. Melo FH; Molognoni F; Morais AS; Toricelli M; Mouro MG; Higa EM; Lopes JD; Jasiulionis MG Free Radic Biol Med; 2011 May; 50(10):1263-73. PubMed ID: 21362470 [TBL] [Abstract][Full Text] [Related]
16. Transcriptional signatures underlying dynamic phenotypic switching and novel disease biomarkers in a linear cellular model of melanoma progression. Pessoa DO; Rius FE; Papaiz DD; Ayub ALP; Morais AS; de Souza CF; da Paixão VF; Setubal JC; Newton-Bishop J; Nsengimana J; Azevedo H; Reis EM; Jasiulionis MG Neoplasia; 2021 Apr; 23(4):439-455. PubMed ID: 33845354 [TBL] [Abstract][Full Text] [Related]
19. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893 [TBL] [Abstract][Full Text] [Related]
20. Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model. Zhao QY; Lei PJ; Zhang X; Zheng JY; Wang HY; Zhao J; Li YM; Ye M; Li L; Wei G; Wu M Clin Epigenetics; 2016; 8():34. PubMed ID: 27034728 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]